Celltrion, Inc. announced its innovative drug development strategy in the rigorous and cutting-edge field of novel drug therapeutics at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Celltrion's presentation, titled 'Unveiling strategy for advancing innovative drug pipelines' took place at the main track. Celltrion's Chairman Jung-Jin Seo and Chief Executive Officer Jin-Seok Seo outlined new drug developments including its next-generation antibody drug conjugate (ADC) platform, with two biobetter ADC candidates CT-P70 and CT-P71.

CT-P70 and CT-P71 are ADCs designed to target solid cancers; with CT-P70 focusing on non-small cell lung cancer (NSCLC) and CT-P71 aiming to treat bladder cancer. These therapeutics leverage the new payload 'PBX-7016,' which demonstrated low toxicity and high tumor growth inhibition (TGI) effects during its development, positioning it as a platform capable of delivering 'best-in-class' therapeutics within the same mechanism of action. In addition, the company announced its plan to develop dual-payload ADCs that incorporate two distinct payloads with complementary mechanisms of action, aiming to deliver a more potent cytotoxic response to cancer cells.

The company also plans to focus on developing multispecific antibodies that selectively target cancer cells or are activated only under specific conditions. CT-P72 is a tumor-selective multispecific antibody which has demonstrated improved on-target off-tumor toxicity through cytotoxic research results showing clear differences between normal tissue cells and cancer cells. The next-generation multispecific antibody therapeutics in development will focus on enhancing safety enhancing tumor selectivity by conditional activation with 'conditionally-active multispecific antibodies (MsAb)' and maximizing therapeutic potential of tumor killing immune cells with 'immuno-oncology multispecific antibodies (MsAb).